Abstract
Patients with hereditary angioedema (HAE) often experience emotional distress and reduced health-related quality of life (HRQoL). Improving quality of life has become an important hallmark of disease management of HAE. Selective inhibition of plasma prekallikrein by antisense oligonucleotide treatment (PKK-LRx) reduced angioedema attacks by more than 90% in a phase 2 trial. The impact of this treatment on HRQoL was a predefined end-point in this trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
